Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED KINGDOM: Cheap, Ultra-Sensitive Colour Test Spots Early HIV, Cancer




 

Medical News Today (10.29.12)

Researchers at the Imperial College of Science, Technology and Medicine, London, United Kingdom, have developed a test to detect viruses and disease biomarkers. This new test is reported to be 10 times more sensitive than the best available today. Researchers Roberto de la Rica and Molly Stevens were able to detect an HIV biomarker called p24 in blood samples as well as low levels of prostate specific antigen (PSA), an early indicator for prostate cancer. The test can be reconfigured to detect known biomarkers of other viruses and diseases. De la Rica noted that the test will enable previously undetectable HIV infections and indicators of cancer to be picked up. The biosensor analyzes serum derived from blood in a disposable, transparent container. The enzyme label of an enzyme-linked immunosorbent assay (ELISA) controls the growth of gold nanoparticles and generates colored solutions. If the marker is present, the reaction generates irregular clumps of nanoparticles that give off a blue color in the solution. If it is absent, the nanoparticles separate into ball-like shapes that give off a reddish color. These reactions can be seen with the naked eye. De la Rica states that this test could be significantly cheaper than those presently being used, and may result in more widespread HIV testing in developing countries. The team plans to approach not-for-profit global health organizations for assistance to develop and manufacture the test for distribution, particularly in low-income countries. The study titled, “Plasmonic ELISA for the Ultrasensitive Detection of Disease Biomarkers with the Naked Eye,” was published online in the journal Nature Nanotechnology, 28 October 2012; DOI:10.1038/nnano.2012.186.



 


Copyright © 2012 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in October 29, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.